Norges Bank’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-60,000
Closed -$792K – 2125
2019
Q2
$792K Buy
+60,000
New +$874K ﹤0.01% 2044

Other funds holding PRVL

Norges Bank's PRVL Position: Q3 2019 in Review

Norges Bank sold out of Prevail Therapeutics (PRVL) in Q3 2019, closing a stake of 60,000 shares — an estimated $792K sold.

Norges Bank first reported a position in PRVL in Q2 2019 and held it in 1 quarter. The position peaked at $792K in Q2 2019. 42 funds tracked by Wall St. Rank hold PRVL as of Q3 2019.

  • Norges Bank reported no remaining Prevail Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Norges Bank sold 60,000 Prevail Therapeutics shares in Q3 2019, an estimated $792K.
  • Norges Bank first reported a position in Prevail Therapeutics in Q2 2019 and held it in 1 quarter.
  • Norges Bank's Prevail Therapeutics position peaked at $792K in Q2 2019.
  • 42 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q3 2019.

Based on Norges Bank's 13F filing for Q3 2019, filed 8 Nov 2019.